Cosentyx tackles psoriasis of nails, hands and feet

| Melissa Leavitt

People with hard-to-treat forms of psoriasis can experience significant improvement on a new biologic drug. According to data presented in June at the World Congress of Dermatology meeting, Cosentyx (secukinumab) delivered clearer skin to patients with psoriasis on the nails, palms and soles. 

Cosentyx was approved by the Food and Drug Administration as a treatment for psoriasis earlier this year. It is an injectable drug that targets a cytokine, or pro-inflammatory protein, known as interleukin 17A (IL-17A). Another drug targeting IL-17A, ixekizumab, is currently being developed by Eli Lilly.

The data comes from two separate placebo-controlled clinical trials. One study, called GESTURE, is a Phase III trial for palmoplantar psoriasis, which affects the palms of the hands and the soles of the feet. The other study, called TRANSFIGURE, is a Phase III trial for nail psoriasis.

After four months of treatment with Cosentyx, a third of patients with palmoplantar psoriasis experienced clear or almost clear skin on the palms and soles, according to the findings. The findings were issued in a statement by Novartis, the company that makes Cosentyx. About 1 percent of patients with palmoplantar psoriasis assigned to take a placebo experienced clear or almost clear skin in the same amount of time, the statement reported.

Patients with nail psoriasis taking Cosentyx experienced more than 45 percent improvement in four months, according to the same statement, compared to about 10 percent improvement experienced by patients on a placebo.

Patients in both studies began to see improvement after about three weeks, according to Dr. George Vratsanos, Executive Global Program Head for Cosentyx.

The most common side effects experienced by patients in the trials were upper respiratory tract infections, the common cold and headaches, Vratsanos said. 

Up to 5.9 percent of patients taking Cosentyx in the palmoplantar psoriasis study, and up to 3 percent of patients on Cosentyx in the nail psoriasis study, experienced serious side effects, according to the data. “The safety profile looked very good, very favorable, and we believe the benefits of treatment clearly outweigh the risks,” Vratsanos said. 

The studies will continue for at least two years, Vratsanos said.

“Both the nails and the palms and soles are very, very difficult to treat,” Vratsanos said. “It’s very exciting to see a dramatic benefit in these patients who clearly have had longstanding disease.”

Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Even during a pandemic, your voice matters.
a young family with psoriasis or psoriatic disease enjoying beach together
This August, we take action together, in support of our community.
Zack Harrison is turning 9 this year, and he’s already a vocal member of our...
A new topical treatment option is now available to patients.
When COVID-19 struck and society shut down, digital advocacy grew up – fast.
FDA Approves Tremfya® for the Treatment of Psoriatic Arthritis
research into new drug treatments in pipeline for psoriasis
More biologics, an oral medication and a topical draw interest from top...
How to stand up for yourself in the face of surprise medical bills.